Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 2/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.42 |
| ▸ | PRCP | P42785 | 2/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diamocaine SCHEMBL592685 | 0.85 | DRD3 (0.42) | DRD3CHRM2CHRM1OPRM1PRCP | |
| SCHEMBL11454802 | 0.74 | HTR7 (0.52) | DRD3OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL11447147 | 0.70 | OPRM1 (0.46) | DRD3OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL11685046 | 0.70 | OPRM1 (0.60) | DRD3OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL11446493 | 0.69 | OPRM1 (0.45) | DRD3OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL19475380 | 0.69 | OPRM1 (0.66) | DRD3OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL7737516 | 0.68 | HTR7 (0.58) | DRD3ALDH1A1POLBCARM1PRMT6 | |
| SCHEMBL11446213 | 0.68 | DRD3 (0.41) | DRD3OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL11682701 | 0.68 | OPRM1 (0.57) | DRD3OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL473377 | 0.67 | DRD4 (0.52) | SIGMAR1ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3863708-B1 | MIXED IONIC CONDUCTORS AND CORRESPONDING DEVICES, SYSTEMS AND METHODS OF MAKING | BATTELLE MEMORIAL INSTITUTE (US) | 2024-09-11 | — | — | EP | claimed |
| US-20230137384-A1 | ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITY | URIGEN PHARMACEUTICALS, INC. | 2023-05-04 | — | — | US | claimed |
| US-11633587-B2 | Mixed ionic electronic conductors: devices, systems and methods of use | BATTELLE MEMORIAL INSTITUTE (US) | 2023-04-25 | — | — | US | claimed |
| US-12605332-B2 | Transdermal delivery formulations | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2026-04-21 | — | — | US | disclosed |
| EP-4683613-A1 | METHOD FOR PREPARING A STERILE HYDROGEL COMPRISING A CROSS-LINKED OR NON-CROSSLINKED POLYSACCHARIDE OR A MIXTURE THEREOF | Teoxane SA (CH) | 2026-01-28 | — | — | EP | disclosed |
| EP-4683614-A1 | METHOD FOR PREPARING A STERILE HYDROGEL COMPRISING A CROSS-LINKED OR NON-CROSSLINKED POLYSACCHARIDE OR A MIXTURE THEREOF | Teoxane SA (CH) | 2026-01-28 | — | — | EP | disclosed |
| US-12491207-B2 | Article of manufacture comprising local anesthetic, buffer, and glycosaminoglycan in syringe with improved stability | VANELTIX PHARMA, INC. (US) | 2025-12-09 | — | — | US | disclosed |
| US-12478612-B2 | Deuterated domperidone compositions, methods, and preparation | CINDOME PHARMA, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| US-12478582-B2 | Method for incorporating organic compounds in solution within a hydrogel | LABORATOIRES VIVACY (FR) | 2025-11-25 | — | — | US | disclosed |
| US-12478576-B2 | Transdermal delivery formulations | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2025-11-25 | — | — | US | disclosed |
| EP-4349414-B1 | FORMULATIONS FOR TRANSDERMAL ADMINISTRATION | DYVE BIOSCIENCES INC (US) | 2025-10-15 | — | — | EP | disclosed |
| US-11305106-B2 | Mixed ionic electronic conductors: devices, systems and methods of use | BATTELLE MEMORIAL INSTITUTE (US) | 2022-04-19 | — | — | US | disclosed |
| US-20220105062-A1 | TRANSDERMAL PENETRANT FORMULATIONS | DYVE BIOSCIENCES, INC. | 2022-04-07 | — | — | US | disclosed |
| US-20220080187-A1 | Mixed Ionic Electronic Conductors: Devices, Systems and Methods of Use | BATTELLE MEMORIAL INSTITUTE | 2022-03-17 | — | — | US | disclosed |
| WO-2022053875-A1 | HYDROGEL COMPRISING A CROSSLINKED AND SILYLATED POLYSACCHARIDE AND PROCESS FOR OBTAINING SAME | Teoxane SA (CH) | 2022-03-17 | — | — | WO | disclosed |
| US-20220062329-A1 | METHOD OF ADMINISTRATION AND TREATMENT | DYVE BIOSCIENCES, INC. | 2022-03-03 | — | — | US | disclosed |
| US-20220047624-A1 | METHOD OF ADMINISTRATION AND TREATMENT | DYVE BIOSCIENCES, INC. | 2022-02-17 | — | — | US | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-20220040225-A1 | METHOD OF ADMINISTRATION AND TREATMENT | DYVE BIOSCIENCES, INC. | 2022-02-10 | — | — | US | disclosed |
| US-20220023336-A1 | METHOD OF ADMINISTRATION AND TREATMENT | DYVE BIOSCIENCES, INC. | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12491207-B2 | Article of manufacture comprising local anesthetic, buffer, and glycosaminoglycan in syringe with improved stability | OGFR, ALOX5, PTGS1 | DRD3 2578/4885CHRM2 2397/4885CHRM1 2318/4885 |
| US-12605332-B2 | Transdermal delivery formulations | NOS1, NOS2, VDR | DRD3 152/4885CHRM2 825/4885CHRM1 653/4885 |
| US-20230137384-A1 | ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITY | OGFR, ALOX5, PTGS1 | DRD3 2578/4885CHRM2 2397/4885CHRM1 2318/4885 |
| US-12478612-B2 | Deuterated domperidone compositions, methods, and preparation | DRD2, DRD1, DRD4 | DRD3 4/4885CHRM2 752/4885CHRM1 894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.